Organon cuts dividend 93% to $0.08/yr; Q1 revenue down 7%, adj EPS $1.02

Organon & Co.

2025-Q1 EPS reported $0.33 revenue$1,513,000,000

Q1 revenue $1.513B, -7% as-reported (-4% ex-FX); GAAP EPS $0.33, non-GAAP adj EPS $1.02.
Board declared quarterly dividend $0.02/share (vs prior $0.28), payable June 12 to holders of record May 12.
Women's Health +10% as-reported (+12% ex-FX) helped by Nexplanon; Biosimilars -17%; Established Brands -11%.
Vtama on track for $150M full-year revenue; affirms 2025 guidance, expects >$900M FCF before one-time costs.
Net income $87M, Adjusted EBITDA $484M (32% margin); company prioritizes deleveraging to net leverage <4.0x by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.